Cabot Wealth Management Inc. Sells 100 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Cabot Wealth Management Inc. trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,615 shares of the company’s stock after selling 100 shares during the quarter. Cabot Wealth Management Inc.’s holdings in IDEXX Laboratories were worth $2,321,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Chicago Partners Investment Group LLC grew its stake in shares of IDEXX Laboratories by 16.7% in the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock worth $340,000 after purchasing an additional 96 shares during the last quarter. National Pension Service grew its position in shares of IDEXX Laboratories by 7.3% in the 3rd quarter. National Pension Service now owns 185,972 shares of the company’s stock valued at $93,957,000 after buying an additional 12,647 shares during the last quarter. Insight Wealth Strategies LLC increased its stake in shares of IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after buying an additional 7,041 shares during the period. Larson Financial Group LLC raised its position in shares of IDEXX Laboratories by 17,238.5% during the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock worth $1,139,000 after acquiring an additional 2,241 shares during the last quarter. Finally, Quest Partners LLC lifted its stake in shares of IDEXX Laboratories by 4,059.4% in the third quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock worth $1,450,000 after acquiring an additional 2,801 shares during the period. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Down 0.0 %

Shares of IDEXX Laboratories stock opened at $452.77 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The stock has a 50 day moving average price of $431.92 and a two-hundred day moving average price of $452.28. The stock has a market capitalization of $37.08 billion, a PE ratio of 42.43, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on IDXX shares. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. Barclays boosted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Morgan Stanley decreased their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Finally, StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,330 shares of company stock valued at $6,161,276. 2.11% of the stock is owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.